Stock chart by TradingView
Logo

$1.31

-0.04 (-2.61%)
Prev Close
1.34
Open
1.31
1.28
Day Low 1.32
Day High
1.305
0.99
52 Week Low 2.99
52 Week High
1.305
Trade Time
02:24 pm
Trade Date
09/01/2026
Today's Performance
Last
$1.31
% Chg
-2.61%
High
1.32
Volume
45.251
Open
1.31
Low
1.28
$ Chg
-0.04
Prev. Close
1.34
After Hours
Price
$1.31
Volume
45.251
Change
-0.04
% Chg
-2.61%
Dividend
Dividend
-
Ex-Div Date
-
Yield
-
Div. Freq.
-
Div. Pay Date
-
Share Information
Year High
2.99
Shares Out
46.99m
PE Ratio
-5.39
Year Low
0.99
Marketcap
61.32m
PB Ratio
6.39
Exchange
NASDAQ
EPS
-0.08

LATEST PRESS RELEASE

Jul 23, 2026
MindWalk Showcases ReefIQ™ for AI Drug Discovery at AMD Advancing AI
Read More
Jul 22, 2026
MindWalk Holdings Corp. (HYFT) Q4 2026 Earnings Call Transcript
Read More
Jul 22, 2026
MindWalk Holdings Corp. (HYFT) Reports Q4 Loss, Misses Revenue Estimates
Read More
Jul 22, 2026
MindWalk Holdings Corp. Reports Fiscal 2026 Results: Revenue Up 46% as the Company Completes Its Pivot to Bio-Native AI Infrastructure
Read More
Jul 13, 2026
MindWalk Holdings Corp. to Report Financial Results and Recent Business Highlights for Fourth Quarter and Full Fiscal Year 2026 on July 22, 2026
Read More
Jul 06, 2026
MindWalk Holdings Corp. (NASDAQ: HYFT) Added to the Russell 3000E Index, Expanding Institutional Investment Opportunity
Read More
Jul 01, 2026
MindWalk (NASDAQ: HYFT) Files Patent for High-Dimensional Biological Data Architecture Powering AI Drug Discovery
Read More
Jun 12, 2026
MindWalk (NASDAQ: HYFT) CEO Dr. Jennifer Bath to Join Absci (NASDAQ: ABSI) and a Leading AI Compute Provider on Jones AI Day Panel on the Future of AI Drug Discovery
Read More
Jun 10, 2026
MindWalk Holdings Corp. (NASDAQ: HYFT) Launches ReefIQ™, a Biological Context Layer for AI Drug Discovery
Read More
Jun 02, 2026
MindWalk's Preclinical Dengue Data Support a HYFT® Computational Prediction: Immunogens Designed on the Predicted Target Elicited Cross-Reactive Antibodies Against Antigens of All Four Dengue Serotypes, Reproduced Across Two Independent Campaigns
Read More